{"schema_version":"secwatch.filing_event.v1","accession":"0000947871-26-000034","form_type":"8-K","ticker":"BSX","cik":"0000885725","company_name":"BOSTON SCIENTIFIC CORP","filed_at":"2026-01-15T23:59:59+00:00","discovered_at":"2026-05-14T18:02:37.919396+00:00","generated_at":"2026-05-16T10:18:14.546377+00:00","sec_items":["7.01","9.01"],"event_type":"m_and_a","sentiment":"positive","materiality_score":0.95,"calibrated_materiality_score":0.95,"confidence":"high","headline":"Boston Scientific to acquire Penumbra for ~$14.5B enterprise value ($374/share)","bullets":["Deal consideration: ~73% cash, ~27% stock; $374 per Penumbra share; enterprise value ~$14.5B.","Penumbra Q4 2025 revenue growth 21.4-22.0%; FY2025 revenue ~$1.4B (+17.3-17.5% YoY).","Transaction expected to close in 2026; subject to Penumbra stockholder approval and customary conditions.","First full year adj. EPS dilutive $0.06-0.08; neutral to slightly accretive in year two.","Expands Boston Scientific into mechanical thrombectomy and neurovascular adjacencies."],"urls":{"canonical":"https://secwatch.observer/filing/0000947871-26-000034","json":"https://secwatch.observer/filing/0000947871-26-000034.json","markdown":"https://secwatch.observer/filing/0000947871-26-000034.md","text":"https://secwatch.observer/filing/0000947871-26-000034.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/885725/000094787126000034/0000947871-26-000034-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/885725/000094787126000034/ss5822817_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-16T10:18:14.546377+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}